Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

CXW

CoreCivic Sells California Detention Facilities for $1.5B

CoreCivic said it completed the July 2 sale of two California detention facilities for an aggregate gross price of $1.5 billion.

The assets were the 2,560-bed California City detention facility, sold for $732.6 million, and the 1,994-bed Otay Mesa detention center, sold for $739.2 million.

After roughly $0.4 billion in federal and state income taxes and transaction expenses, CoreCivic expects net proceeds of about $1.1 billion.

The company said it plans to use part of the cash to reduce debt. That includes paying down its bank credit facility, which currently carries $270.0 million on the revolving credit facility, $107.8 million on the initial term loan, and $100.0 million on the incremental term loan. CoreCivic also said it expects to repay the remaining $238.5 million outstanding on its 4.75% senior notes due October 2027.

CoreCivic said any remaining proceeds may go toward general corporate purposes, including additional debt reduction and share repurchases, subject to leverage limits in its credit documents.

The company said it expects to keep managing both facilities under existing ICE contracts, though those terms could change with the ownership transfer. The California City management contract runs through August 2027, while the Otay Mesa contract runs through December 2029 and includes a five-year extension option.

CoreCivic also said it has been in discussions with ICE about possible sales of additional detention facilities. Following these announcements, the company's shares moved 1.39%, and are now trading at a price of $31.46. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS